| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2011 | CN101951926A Composition containing microRNA-21 inhibitor for enhancing radiation sensitivity |
| 01/19/2011 | CN101951925A Angiogenesis inhibition |
| 01/19/2011 | CN101951924A Micro-RNAs of the MIR-15 family modulate cardiomyocyte survival and cardiac repair |
| 01/19/2011 | CN101951923A Liquid nucleotides/nucleosides-containing product |
| 01/19/2011 | CN101951922A Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
| 01/19/2011 | CN101951921A Method and means for the treatment of cachexia |
| 01/19/2011 | CN101951920A Combination of vitamin D and 25-hydroxyvitamin D 3 |
| 01/19/2011 | CN101951919A Combined use of 25-hydroxy-vitamin D3 and vitamin D3 for improving bone mineral density and for treating osteoporosis |
| 01/19/2011 | CN101951918A Treating hyperglycemia with 25-hydroxyvitamin D3 |
| 01/19/2011 | CN101951917A Treating hypertension with 25-hydroxyvitamin D3 |
| 01/19/2011 | CN101951916A Use of 25-hydroxy-vitamin D3 to affect human muscle physiology |
| 01/19/2011 | CN101951915A Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and WNT signaling |
| 01/19/2011 | CN101951914A Anbrosteeone derivatives and method of use thereof |
| 01/19/2011 | CN101951913A Poly aromatic sodium channel blockers |
| 01/19/2011 | CN101951912A Treatment of post-traumatic stress disorder |
| 01/19/2011 | CN101951911A 2-amino purine derivatives and their use as anti-herpetic agents |
| 01/19/2011 | CN101951910A Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib |
| 01/19/2011 | CN101951909A Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 01/19/2011 | CN101951908A Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| 01/19/2011 | CN101951907A Antitumoral agents with a benzophenanthridine structure and formulations containing them |
| 01/19/2011 | CN101951906A Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases |
| 01/19/2011 | CN101951905A Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin |
| 01/19/2011 | CN101951904A Benzothiazole and benzoxazole derivatives and methods of use |
| 01/19/2011 | CN101951903A Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases |
| 01/19/2011 | CN101951902A Valsartan solid oral dosage forms and methods of making such formulations |
| 01/19/2011 | CN101951901A Use of phthalimide derivatives in the treatment of diseases |
| 01/19/2011 | CN101951900A Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 01/19/2011 | CN101951899A Abnormal intraocular pressure treatment |
| 01/19/2011 | CN101951898A Medical use of 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate and dihydrogen phosphate |
| 01/19/2011 | CN101951897A Use of amidoxime carboxylic acid esters and N-hydroxyguanidine carboxylic acid esters for producing prodrugs |
| 01/19/2011 | CN101951894A Formulations of flibanserin |
| 01/19/2011 | CN101951891A Solid pharmaceutical dosage form |
| 01/19/2011 | CN101951889A Imatinib compositions |
| 01/19/2011 | CN101951886A Enhancing photostabilization of oxymetazoline |
| 01/19/2011 | CN101951884A Compositions and methods for the treatment of bladder cancer |
| 01/19/2011 | CN101951879A Polysaccharide gel formulation |
| 01/19/2011 | CN101951794A Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota |
| 01/19/2011 | CN101951790A A palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent |
| 01/19/2011 | CN101951777A Tetrahydrofuropyridones |
| 01/19/2011 | CN101951776A Tetrahydro-1H-pyrrolo fused pyridones |
| 01/19/2011 | CN101951775A Tetrahydrothieno pyridines |
| 01/19/2011 | CN101951773A Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers |
| 01/19/2011 | CN101951770A Hcv protease inhibitors and uses thereof |
| 01/19/2011 | CN101951769A Hcv protease inhibitors and uses thereof |
| 01/19/2011 | CN101951768A Neurogenic compounds |
| 01/19/2011 | CN101951766A IAP inhibitors |
| 01/19/2011 | CN101948887A Preparation method and application of recombinant phycocyanobilin |
| 01/19/2011 | CN101948835A Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| 01/19/2011 | CN101948716A Anhydrous hand washing agent |
| 01/19/2011 | CN101948566A Multifunctional polymer for resisting fungi and cancers and performing cell imaging and preparation method thereof |
| 01/19/2011 | CN101948549A Sulphating modification method of gynostemma pentaphylla polysaccharide |
| 01/19/2011 | CN101948506A Finasteride conjugate and application thereof to preparation of medicament for treating prostate |
| 01/19/2011 | CN101948500A New derivative of camptothecin 20-site coupled bile acid |
| 01/19/2011 | CN101948499A Pseudoginsenoside G1 and extraction method and medicinal applications thereof |
| 01/19/2011 | CN101948498A Pseudo-ginsenoside G2, extraction method and drug application thereof |
| 01/19/2011 | CN101948497A Ginsenoside R10, extraction method and pharmaceutical use thereof |
| 01/19/2011 | CN101948488A Ruthenium-selenium coordination compound and application thereof in preparing fluorescent probe and antineoplastic medicine |
| 01/19/2011 | CN101948485A Alpha crystal form of tenofovir disoproxil fumarate, and preparation method and application thereof |
| 01/19/2011 | CN101948475A Isoflavone derivate-chromene (chroman) oxazines compound, preparation method and application thereof |
| 01/19/2011 | CN101948473A New NEO-clerodane diterpenoid compound and application thereof |
| 01/19/2011 | CN101948472A Novel staurosporine analogue and preparation method and applications thereof |
| 01/19/2011 | CN101948470A Application of phenanthroindolizidine alkaloid organic acid salt derivative in medicine |
| 01/19/2011 | CN101948467A Thiazoleamide compound and use thereof for the preparation of anti-malignant tumor medicines |
| 01/19/2011 | CN101948464A 3,4,6-triaryl-(1,3)-oxazine-2-ketone compound as well as preparation method and application thereof |
| 01/19/2011 | CN101948462A Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity |
| 01/19/2011 | CN101948458A Baicalein derivatives with antitumor activity and application thereof in medicines |
| 01/19/2011 | CN101948456A Rhizoma zedoariae inner ester derivant with antitumor activity and preparation method thereof |
| 01/19/2011 | CN101948453A Novel NEO-clerodane typed diterpene compound and application thereof |
| 01/19/2011 | CN101948442A Preparation method of linezolid and preparation thereof |
| 01/19/2011 | CN101948439A Extraction method and application to medicine of active alkaloid compounds in cervus nippon temminck |
| 01/19/2011 | CN101948430A Sinomenine derivative and preparation method and applications thereof |
| 01/19/2011 | CN101948429A 1-methyl-7H-indene[1, 2-b]quinolinetrifluoromesylate-7-(4-dimethylamino) benzyl alkene derivant and preparation thereof |
| 01/19/2011 | CN101948428A 1-methyl-5H-indene (1,2-b) pyridine trifluoromethanesulfonic salt-5-(4-dimethylamino group) benzylidene derivative and preparation method thereof |
| 01/19/2011 | CN101948425A Compound as glucocorticoid ligand, pharmaceutical composition including same, kit and method for preparing same |
| 01/19/2011 | CN101948418A Hydroxyproline structure-containing HIV-1 protease inhibitor as well as preparation method and application thereof |
| 01/19/2011 | CN101948416A Compound used for treating metabolic disorder |
| 01/19/2011 | CN101948412A Site-15 deacetylation and site-13 straight-chain sulfamic acid substituted hypocrellin derivative, preparation method and application thereof |
| 01/19/2011 | CN101948403A New antibacterial compound |
| 01/19/2011 | CN101948381A Novel antineoplastic compound |
| 01/19/2011 | CN101948380A Perturbed membrane-binding compounds and methods of using the same |
| 01/19/2011 | CN101947368A Flame-retardant body strengthening safety clothing of nano-element fiber fabric |
| 01/19/2011 | CN101947319A Medicinal composition for treating and preventing discomfort of people with myocardial ischemia |
| 01/19/2011 | CN101947311A Plasma substitute combination |
| 01/19/2011 | CN101947309A Human basic fibroblast growth factor eye drops and preparation method thereof |
| 01/19/2011 | CN101947306A Treatment of T-cell mediated diseases |
| 01/19/2011 | CN101947292A Chinese medicinal oral preparation for treating uterine cancer, cervical cancer and ovarian cancer |
| 01/19/2011 | CN101947290A Medicament with yin-nourishing effect |
| 01/19/2011 | CN101947280A Medicament for treating leg pain and leg numbness |
| 01/19/2011 | CN101947276A Chinese medicinal composition for treating rheumatic arthritis |
| 01/19/2011 | CN101947269A Medicine for treating viral herpes |
| 01/19/2011 | CN101947267A Solid fragrant anti-dizziness agent and preparation method thereof |
| 01/19/2011 | CN101947266A Solid aromatic sobering-up agent and preparation method thereof |
| 01/19/2011 | CN101947264A Chinese and western compound suppository for treating dog endometritis and preparation method thereof |
| 01/19/2011 | CN101947257A Nano silver-selenium negative ion strongly-antibacterial aerosol for preventing and curing rhinitis and influenza |
| 01/19/2011 | CN101947253A External compound preparation for curing tinea corporis as well as preparation method and content measuring method thereof |
| 01/19/2011 | CN101947247A Method for preparing ginkgodipyidamolum injection |
| 01/19/2011 | CN101947240A Mixed sugar electrolyte drug composite injection |
| 01/19/2011 | CN101947239A Drug for treating psoriasis |
| 01/19/2011 | CN101947237A Externally-applied hypochlorous acid liquid with functions of oxidizing, disinfecting, expelling and removing toxins |
| 01/19/2011 | CN101947235A Medicamentous application of CPE (Conjugated Polyelectrolyte) |